PRGO · XBRL financial data

Perrigo Company financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PRGO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 28, 2026	Q2 FY26Jun 27, 2026
Revenue from contracts with customers	1,124	1,157*	1,082	1,066	1,088	1,138*	1,044	1,056	1,043	1,110*	969	1,023
Cost of goods and services sold	713	730*	724	671	683	752*	652	693	666	747*	644	709
Gross profit	411	427*	358	395	404	386*	392	363	377	362*	326	314
Research and development	30	30*	29	29	26	28*	27	22	25	22*	25	24
General and administrative	126	129*	130	126	117	95*	112	113	94	117*	115	100
Total operating expenses	349	443*	413	421	324	272*	345	318	305	1,649*	698	291
Other operating income (expense)	—	year only	(34)	(20)	7	42*	(5)	(12)	(13)	(0)*	—	—
Operating income (loss)	62	(16)*	(55)	(27)	80	114*	47	45	73	(1,287)*	(372)	24
Other income (expense)	1	1*	(0)	(3)	4	0*	0	(3)	(10)	(1)*	6	121
Income tax expense (benefit)	4	(27)*	(103)	32	39	112*	8	4	10	83*	(19)	17
Net income (loss)	14	(32)*	2	(108)	(21)	(45)*	(6)	(8)	8	(1,418)*	(399)	75
Earnings per share, basic USD per share	0.10	(0.24)*	0.01	(0.79)	(0.15)	(0.32)*	(0.05)	(0.06)	0.05	(10.16)*	(2.87)	0.54
Earnings per share, diluted USD per share	0.10	(0.24)*	0.01	(0.79)	(0.15)	(0.32)*	(0.05)	(0.06)	0.05	(10.19)*	(2.87)	0.53
Weighted average shares, basic millions of shares	136	135*	137	137	138	138*	138	138	139	140*	139	139
Weighted average shares, diluted millions of shares	137	133*	138	137	138	137*	138	138	139	139*	139	140

Balance sheet

CSV

Fiscal quarters (PRGO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 28, 2026	Q2 FY26Jun 27, 2026
Cash and cash equivalents	598	751	659	543	1,464	559	410	454	432	532	357	400
Accounts receivable	738	740	780	726	786	642	717	678	644	613	697	710
Inventory	1,150	1,141	1,121	1,116	1,134	1,082	1,155	1,216	1,227	1,149	1,121	1,065
Prepaid and other current assets	280	201	247	282	312	199	229	267	295	231	272	278
Total current assets	2,765	2,833	2,806	2,959	3,708	2,482	2,533	2,615	2,879	2,797	2,712	2,452
Property and equipment, net	903	916	911	910	909	918	913	914	903	899	878	849
Right-of-use asset	200	184	177	190	182	175	170	173	170	168	162	156
Goodwill	3,550	3,529	3,493	3,370	3,421	3,320	3,375	3,479	3,360	2,050	1,702	1,694
Total assets	10,758	10,809	10,640	10,397	11,203	9,648	9,760	10,094	10,084	8,535	7,983	7,610
Accounts payable	433	478	454	472	459	495	502	489	470	475	435	400
Accrued liabilities	262	335	359	219	227	239	254	328	363	—	—	—
Current portion of long-term debt	38	441	441	441	441	36	36	36	37	37	11	11
Total current liabilities	1,008	1,586	1,555	1,488	1,451	1,044	1,074	1,126	1,145	1,013	998	1,055
Long-term debt	4,049	3,633	3,625	3,617	4,313	3,582	3,591	3,616	3,608	3,604	3,621	3,283
Lease liability, non-current	173	160	153	164	160	154	150	152	153	152	147	139
Total liabilities	6,020	6,041	5,953	5,852	6,637	5,328	5,396	5,622	5,638	5,600	5,485	5,094
Accumulated deficit	(2,048)	(2,080)	(2,078)	(2,187)	(2,208)	(2,252)	(2,259)	(2,267)	(2,259)	(3,678)	(4,076)	(4,002)
Total stockholders' equity	4,738	4,768	4,687	4,545	4,566	4,319	4,364	4,472	4,447	2,936	2,499	2,516
Total liabilities and equity	10,758	10,809	10,640	10,397	11,203	9,648	9,760	10,094	10,084	8,535	7,983	7,610
Common shares outstanding (cover page) millions of shares	136	136	136	136	136	136	137	138	138	138	138	139

Cash flows

CSV

Fiscal quarters (PRGO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 28, 2026	Q2 FY26Jun 27, 2026
Net income (loss)	14	(32)*	2	(108)	(21)	(45)*	(6)	(8)	8	(1,418)*	(399)	75
Stock-based compensation	15*	11*	16	23*	6*	20*	12	17*	13*	13*	14	7*
Depreciation and amortization	91*	86*	81	82	82	80*	80	86	85	86*	83	96*
Net cash from operating activities	125*	209*	(1)	10*	42*	313*	(65)	76*	52*	175*	(114)	83*
Purchases of property and equipment	32*	27*	25	28*	27*	38*	26	19*	22*	27*	14	14*
Net cash from investing activities	(31)*	(23)*	(24)	(73)*	213*	(37)*	(26)	(4)*	(21)*	(25)*	(12)	349*
Dividends paid	39*	38*	38	38*	38*	40*	41	39*	40*	40*	40	40*
Proceeds from long-term debt	0*	295*	—	—	—	(2)*	0	0*	0*	0*	428	0*
Repayments of long-term debt	9*	301*	10	10*	401*	1,109*	9	9*	9*	9*	424	335*
Net cash from financing activities	(43)*	(45)*	(60)	(50)*	653*	(1,154)*	(62)	(54)*	(50)*	(54)*	(45)	(389)*
Net change in cash	43*	153*	(93)	(116)*	921*	(905)*	(142)	37*	(20)*	100*	(174)	40*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.